Nuformix Plc (GB:NFX) has released an update.
Nuformix plc, a pharmaceutical development company, has released a prospectus for the issuance of 600 million new ordinary shares as part of a £300,000 fundraising initiative. The proceeds are intended to finalize a licensing or option agreement for its NXP002 programme by March 2025, although this outcome is not guaranteed. If additional revenue is not secured, the company may face a working capital shortfall, potentially putting its operations at risk.
For further insights into GB:NFX stock, check out TipRanks’ Stock Analysis page.
